Inovio (INO) Checks First Important Box in Zika Trial - Stifel
Tweet Send to a Friend
Stifel analyst Thomas Shrader reiterated a Buy rating and $11 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE